NCT05917353

Brief Summary

Taiwan is about to enter a super-aged society in 2025. The health problems of the elderly are getting more and more attention. Among these geriatric issues, sarcopenia is an important issue. Sarcopenia is the culprit of disability in old age. It is characterized by persistent and general loss of skeletal muscle mass and function throughout the body, which may lead to disability, decreased quality of life, and even inability to take care of yourself and an increased risk of death. Human skeletal muscle decreases with age. After the age of 40, muscle mass will be lost at a rate of 8% per decade; after the age of 70, it will be lost at a faster rate of 15% per decade in average. Although all elderly will lose muscle mass due to aging, the degree and speed of loss vary from person to person. In addition to aging, it may also be caused by chronic diseases. Exercise intervention and nutritional intervention are the first choices for sarcopenia intervention. Regarding nutritional requirements, the elderly need at least 15 grams of essential amino acids per day for muscle building. Among them, leucine is the most important, which can increase protein production and reduce decomposition. Foods rich in leucine include soybeans, fish or beef. However, elderly people may not be able to get enough protein from their daily diet smoothly, often because of dysphagia, such as dental problems or chewing and swallowing problems. Therefore, oral nutritional supplements are relatively important for the improvement of muscle mass. Nutritional Supplement Hinex Jelly has 303 calories per serving, contains up to 15g of high-quality protein and a high amount of branched-chain amino acids, which is beneficial for muscle synthesis and tissue repair, plus a variety of minerals, vitamins, water-soluble dietary fiber, hydrolyzed collagen and other ingredients can strengthen nutritional supplements, maintain good health. In summary, this study intends to explore the effect of Hinex Jelly nutritional supplemental intervention on muscle mass quality and quantity changes by means of randomized intervention and controlled trials.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 5, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 23, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

January 18, 2024

Status Verified

June 1, 2023

Enrollment Period

2.3 years

First QC Date

June 5, 2023

Last Update Submit

January 17, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • Change from Baseline Appendicular skeletal muscle mass index at 8 weeks

    Appendicular skeletal muscle mass index assessed using the Inbody S10

    8 weeks after the first session

  • Change from Baseline handgrip strength at 8 weeks

    assessed with a Jamar handheld dynamometer in kilograms

    8 weeks after the first session

  • Change from Baseline performance on the 5-repetition sit-to-stand test at 8 weeks

    assessed in seconds

    8 weeks after the first session

  • Change from Baseline performance on 6-metre walk test at 8 weeks

    assessed in seconds

    8 weeks after the first session

Study Arms (2)

Hinex Jelly Nutritional Supplement Intervention Group

EXPERIMENTAL

Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after), diet and exercise health education was given, with daily intervention of Hinex Jelly nutritional supplements 1 serving per day during 0th to 8th Week;

Dietary Supplement: Hinex Jelly

Routine care group

NO INTERVENTION

Week 0th, Week 4th (14 days before and after), Week 8th (14 days before and after), Week 12th (14 days before and after), the subjects were given regular dietary and exercise health education.

Interventions

Hinex JellyDIETARY_SUPPLEMENT

1. Name: Hinex Jelly 2. Dosage form: Semi-solid jelly/ A-114001297-00000-2 3. Dose(s): 300g/pack (per serving) 4. Dosing schedule: one pack (serving) per day 5. Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food.

Hinex Jelly Nutritional Supplement Intervention Group

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults over the age of 50 (include 50 years old).
  • Can cooperate with the study.
  • No surgical intervention within 3 months.

You may not qualify if:

  • Those who have obvious difficulty in movement (such as amputation) and cannot cooperate with the study.
  • Those who are equipped with pacemakers or internal electronic medical devices.
  • Pregnant women.
  • Use of drugs or interventional therapy that may affect changes in body weight or muscle mass (such as other oral nutritional supplements, medicine, weight reduction medicine, bariatric gastric endoscopy therapy, bariatric surgery, acupuncture, acupuncture, electrical stimulation, etc.).
  • Allergic to dairy or soy products.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kaohsiung Medical University Hospital

Kaohsiung City, 807, Taiwan

RECRUITING

MeSH Terms

Conditions

Muscle Weakness

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms

Central Study Contacts

Chen-Cheng Yang, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2023

First Posted

June 23, 2023

Study Start

March 1, 2023

Primary Completion

June 30, 2025

Study Completion

June 30, 2025

Last Updated

January 18, 2024

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations